- Home
- BREA vs APLM Comparison
BREA vs APLM Comparison
Compare BREA & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- APLM
- Stock Information
- Founded
- BREA 2022
- APLM 2016
- Country
- BREA Ireland
- APLM United States
- Employees
- BREA N/A
- APLM N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- APLM Blank Checks
- Sector
- BREA Consumer Discretionary
- APLM Finance
- Exchange
- BREA Nasdaq
- APLM Nasdaq
- Market Cap
- BREA 13.3M
- APLM 12.3M
- IPO Year
- BREA 2023
- APLM N/A
- Fundamental
- Price
- BREA $0.80
- APLM $9.56
- Analyst Decision
- BREA
- APLM Strong Buy
- Analyst Count
- BREA 0
- APLM 2
- Target Price
- BREA N/A
- APLM $425.00
- AVG Volume (30 Days)
- BREA 1.3M
- APLM 36.2K
- Earning Date
- BREA 01-03-2025
- APLM 02-15-2025
- Dividend Yield
- BREA N/A
- APLM N/A
- EPS Growth
- BREA N/A
- APLM N/A
- EPS
- BREA N/A
- APLM N/A
- Revenue
- BREA $2,872,101.00
- APLM $2,101,000.00
- Revenue This Year
- BREA N/A
- APLM N/A
- Revenue Next Year
- BREA N/A
- APLM N/A
- P/E Ratio
- BREA N/A
- APLM N/A
- Revenue Growth
- BREA 2338.69
- APLM 70.54
- 52 Week Low
- BREA $0.50
- APLM $6.50
- 52 Week High
- BREA $3.00
- APLM $91.00
- Technical
- Relative Strength Index (RSI)
- BREA 51.27
- APLM 46.48
- Support Level
- BREA $0.71
- APLM $9.50
- Resistance Level
- BREA $0.82
- APLM $10.67
- Average True Range (ATR)
- BREA 0.13
- APLM 0.92
- MACD
- BREA -0.00
- APLM -0.04
- Stochastic Oscillator
- BREA 14.61
- APLM 13.17
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.